Union City

Researchers are conducting a prospective multi-center observational study to optimize and evaluate a circulating free DNA cfDNA biomarker panel aimed at detecting colorectal cancer CRC and advanced adenomas. The study involves enrolling eligible subjects from the United States, including those suspected of having advanced adenomas or newly diagnosed with CRC scheduled for surgery, as well as average-risk individuals scheduled for routine colonoscopy. Participants will be assigned to one of two groups those with suspected advanced adenomas or new CRC diagnoses awaiting surgery, and those at average risk undergoing screening colonoscopy. Blood samples will be collected, with up to 40 ml drawn at the study visit, and clinical data will be gathered to assess the performance of the cfDNA biomarker panel. The study focuses on evaluating this diagnostic test through sample collection and marker testing. During the study, participants will provide blood samples and undergo clinical data collection. Researchers will monitor the samples collected within 12 months for plasma cfDNA marker testing. The study involves informed consent and ensures participants can comprehend and agree to participation. The total participation period may vary, but assessments focus on blood sampling and related testing to measure biomarker performance related to CRC and advanced adenomas.